Main Article Content


Behçet’s disease (BD) is a chronic, relapsing, inflammatory disease characterized by recurrent oral aphthae and any of several systemic manifestations that include genital aphthae, ocular disease, skin lesions, neurologic disease, vascular disease, or arthritis. Hippocrates may had described BD in the fifth century B.C.; however, the first official description of the syndrome was attributed to the Turkish dermatologist Hulusi Behçet in 1924. In 1930, the Greek physician Adamantiades reported a patient with inflammatory arthritis, oral and genital ulcers, phlebitis, and iritis.1 Since then, the syndrome has been referred to as BD.1,2 The manifestations of BD are thought to be caused by an underlying vasculitis. Although this disease is recognized worldwide, the prevalence is highest in the eastern Mediterranean, the Middle Eastern, and East Asian countries, thus the nickname Silk Road disease. The disease tends to be more severe in areas where it is more common. Prevalence rates all over the world are increasing, probably because of improved recognition and reporting. Behçet’s disease occurs primarily in young adults. The mean age at onset is between 25 and 30 years. The incidence of disease in males and females is approximately equal along the Silk Road, but in Japan, Korea, and Western countries the disease occurs more frequently in women. Case
confirmation can be challenging because many patients labeled as having BD have oral ulcers as the primary or sole manifestation.3

Article Details

How to Cite
Umami, V., & Setiyohadi, B. (2018). Complete manifestations of Behçet’s disease. Indonesian Journal of Rheumatology, 2(1).


  1. Adamantiades B. A case of recurrent hypopyon iritis. Medical Society of Athens 1930;586–93.
  2. Feigenbaum A. Description of Behçet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol 1956;40:355–7.
  3. International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. The Lancet 1990;335:1078–80.
  4. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 1999;341 (17):1284–91.
  5. Barnes, CG, Yazici, H. Behçet’s syndrome. Rheumatology (Oxford) 1999;38:1171.
  6. Demirkesen C, Tüzüner N, Mat C, Senocak M, Büyükbabani M, Tüzün Y, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet’s syndrome. Am J Clin Pathol 2001;116(3):341–6.
  7. Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001;60(11):1074–6.
  8. Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet’s disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002;29(11):2393–6.
  9. Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Behçet’s disease. Scand J Immunol 1996;43(4):464–71.
  10. de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Infl amm 2000;9(2):85–92.
  11. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendation for the management of Behçet’s disease. Ann Rheum Dis 2008;67:1656–62.
  12. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet’s disease: an analysis of 880 patients. Am J Ophthalmol 2004;138(3):373–80

Most read articles by the same author(s)